Latest Biotech News

Function Health raised $298 million in a Series B led by Redpoint Ventures, valuing the lab-testing startup at roughly $2.5 billion. The company sells subscription-based access to over 160 lab...

Tessera Therapeutics confirmed it will begin the first human trial of its in vivo gene‑writing platform, testing an approach intended to install permanent genetic changes without double-strand...

Contineum Therapeutics reported topline results from its Phase 2 VISTA trial of PIPE‑307, an M1 receptor antagonist developed in partnership with Johnson & Johnson, and the study missed its...

AnaptysBio filed a verified complaint in Delaware Chancery Court claiming Tesaro (a GSK subsidiary) materially breached a 2014 collaboration and exclusive license agreement related to Jemperli and...

UK Biobank released the final tranche of metabolomics data covering 249 blood metabolites for roughly 500,000 participants, creating the largest public metabolomics resource to date. The dataset...

Hepta, founded by former Grail veterans, published proof‑of‑concept data showing cell‑free DNA (cfDNA) methylation signatures reflect liver tissue biology, including fibrosis and pathway activity....

Multiple outlets reported that the U.S. Centers for Disease Control and Prevention revised language on a vaccine‑safety webpage to state that claims vaccines do not cause autism are not...

Moderna disclosed a $1.5 billion financing package as part of a strategic plan to scale seasonal vaccine manufacturing and redeploy revenue into oncology and rare disease programs, aiming to reach...

Abbott announced a definitive agreement to buy Exact Sciences for roughly $21–23 billion, moving the medical-device giant into multi-cancer screening and precision oncology diagnostics. The deal...

GSK has selected two Flagship Pioneering portfolio companies — Profound (proteomics) and Quotient (somatic genomics) — as the first collaborators under a multi‑program discovery framework intended...

Contineum Therapeutics reported topline results from its Phase 2 VISTA study of PIPE‑307 in relapsing‑remitting multiple sclerosis (RRMS); the trial missed its primary visual acuity efficacy...

Researchers led by David Liu at the Broad Institute unveiled PERT — prime editing‑installed suppressor tRNAs — a strategy to convert an endogenous tRNA into a suppressor that can restore protein...

Tessera Therapeutics confirmed it will start the first‑in‑human trial of its in vivo gene‑writing platform next month, filing clinical steps to test the technology in adults with a rare genetic...

Profluent closed a $106 million financing round led by Altimeter Capital and Bezos Expeditions to expand large‑scale AI models for protein design across therapeutics, agriculture and...

Function Health raised a $298 million Series B led by Redpoint Ventures, valuing the lab‑testing subscription startup at approximately $2.5 billion. The company offers consumers direct access to...

Bayer won accelerated FDA approval for Hyrnuo (sevabertinib) in adults with advanced HER2‑mutant non‑small‑cell lung cancer after prior systemic therapy. The decision positions Hyrnuo to compete...

Nurix Therapeutics announced a targeted workforce reduction while initiating a pivotal Phase 2 (DAYBreak) trial of bexobrutideg, an oral BTK degrader aimed at relapsed or refractory chronic...

Multiple health organizations and scientific outlets flagged a revision to the CDC’s vaccine safety web content that introduced language suggesting uncertainty about whether vaccines can cause...

Abbott announced a definitive agreement to acquire Exact Sciences, the maker of Cologuard and Oncotype DX, in a transaction that values Exact at roughly $21 billion in cash and about $23 billion...

The FDA granted approval to Bayer’s oral HER2‑directed drug Hyrnuo for adults with locally advanced or metastatic HER2‑mutant non‑small cell lung cancer, clearing a new targeted option for...